Overall, the current data for prostate cancer strongly promotes the use of the HDAC inhibitors (at sub-cytotoxic doses) as radiosensitizers in a combination treatment in much the same way as exploited in clinical trials for other cancer types [106]. Here, HDAC9 is linked to prostate cancer.